The relation of proteoglycans, serum amyloid P and Apo E to amyloidosis current status, 2000

Amyloid

Volumn 7, Issue 1, 2000, Pages 23-25

  Kisilevsky, Robert ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

AA; Amyloid; Apo E; A ; Heparan sulfate; IAPP; Serum amyloid P

Indexed keywords

APOLIPOPROTEIN E; HEPARAN SULFATE; PERLECAN; PROTEOGLYCAN; PROTEOHEPARAN SULFATE; SERUM AMYLOID P;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AMYLOIDOSIS; ANIMAL TISSUE; ARTICLE; BASEMENT MEMBRANE; EXTRACELLULAR MATRIX; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN CONFORMATION; PROTEIN DETERMINATION; PROTEIN LOCALIZATION;

EID: 0034110874     PISSN: 13506129     EISSN: None     Source Type: Journal    
DOI: 10.3109/13506120009146820     Document Type: Article

References (26)

1. Westermark P (1997). Classification of amyloid fibril proteins and their precursors: an ongoing discussion. Amyloid: Int J Exp Clin Invest 4, 216-218
2. Boyd W, (1932). A Textbook of Pathology: An Introduction to Medicine, pp. 107. (Philadelphia:Lea and Febiger)
3. Bitter T and Muir H (1966). Mucopolysaccharides of whole human spleens in generalized amyloidosis. J Clin Invest 45, 963-975
4. Snow AD and Kisilevsky R (1988). A close ultrastructural relationship between sulphated proteoglycans and AA amyloid fibrils. Lab Invest 57, 687-698
5. Inoue S and Kisilevsky R (1996). A high resolution ultrastructural study of experimental murine AA amyloid. Lab Invest 74, 670-683
6. Ailles L, Kisilevsky R and Young ID (1993). Induction of perlecan gene expression precedes amyloid formation during experimental murine AA amyloidogenesis. Lab Invest 69, 443-448
7. Snow AD, Kisilevsky R, Stephens C and Anastassiades T (1987). Characterization of tissue and plasma glycosaminoglycans during experimental AA amyloidosis and acute inflammation.Quantitative and qualitative analysis. Lab Invest 56, 665-675
8. McCubbin WD, Kay CM, Narindrasorasak S and Kisilevsky R (1988). Circular dichroism and fluorescence studies on two murine serum amyloid A proteins. Biochem J 256, 775-783
9. De Beer MC, de Beer FC, McCubbin WD, Kay CM and Kindy MS (1993). Structural prerequisites for serum amyloid A fibril formation. J Biol Chem 268, 20606-20612
10. Kisilevsky R, Lemieux LJ, Fraser PE, Kong XQ, Hultin PG and Szarek WA (1995). Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: Implications for Alzheimer's disease. Nat Med 1, 143-148
11. Kisilevsky R and Fraser P (1996). Proteoglycans and amyloid fibrillogenesis. Ciba Foundation Symposium 199, 58-72
12. Castillo GM, Cummings JA, Yang WH, Judge ME, Sheardown MJ, Rimvall K, Hansen JB and Snow AD (1998). Sulfate content and specific glycosaminoglycan backbone of perlecan are critical for perlecan's enhancement of islet amyloid polypeptide (amylin) fibril formation. Diabetes 47, 612-620
13. Ancsin JB and Kisilevsky R (1999). The heparin/heparan sulfate-binding site on apo-serum amyloid A: implications for the therapeutic intervention of amyloidosis. J Biol Chem 274, 7172-7181
14. Arikawa-Hirasawa E, Watanabe H, Takami H, Hassell JR and Yamada Y (1999). Perlecan is essential for cartilage and cephalic development. Nat Genet 23, 354-358
15. Pepys MB, Booth DR, Hutchinson WL, Gallimore JR, Collins PM and Hohenester E (1997). Amyloid P component. A critical review. Amyloid: Int J Exp Clin Invest 4, 274-295
16. Baltz ML, Caspi D, Evans DJ, Rowe IF, Hind CRK and Pepys MB (1986). Ciculating amyloid P component is the precursor of amyloid P component in tissue amyloid deposits. Clin Exp Immunol 66, 691-700
17. Botto M, Hawkins PN, Bickerstaff MCM, Herbert J, Bygrave AE, Mcbride A, Hutchinson WL, Tennent GA, Walport MJ and Pepys MB (1997). Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene. Nat Med 3, 855-859
18. Danielsen B, Sorensen IJ, Nybo M, Nielsen EH, Kaplan B and Svehag SE (1997). Calcium-dependent and -independent binding of the pentraxin serum amyloid P component to glycosaminoglycans and amyloid proteins: Enhanced binding at slightly acid pH. Biochim Biophys Acta 1339, 73-78
19. Hawkins PN, Richardson S, Macsweeney JE, King AD, Vigushin DM, Lavender JP and Pepys MB (1993). Scintigraphic quantification and serial monitoring of human visceral amyloid deposits provide evidence for turnover and regression. Quart J Med 86, 365-374
20. Gallo G, Wisniewski T, Choi-Miura NH, Ghiso J and Frangione B (1994). Potential role of apolipoprotein-E in fibrillogenesis. Am J Pathol 145, 526-530
21. Mahley RW and Huang YD (1999). Apolipoprotein E: from atherosclerosis to Alzheimer's disease and beyond. Curr Opin Lipidol 10, 207-217
22. Bales KR, Verina T, Dodel RC, Du YS, Altstiel L, Bender M, Hyslop P, Johnstone EM, Little SP, Cummins DJ, Piccardo P, Ghetti B and Paul SM (1997). Lack of apolipoprotein E dramatically reduces amyloid β- peptide deposition. Nat Genet 17, 263-264
23. Kindy MS and Rader DJ (1998). Reduction in amyloid A amyloid formation in apolipoprotein-E- deficient mice. Am J Pathol 152, 1387-1395
24. Chan W, Fornwald J, Brawner M and Wetzel R (1996). Native complex formation between apolipoprotein E isoforms and the Alzheimer's disease peptide Aβ. Biochemistry 35, 7123-7130
25. Golabek AA, Soto C, Vogel T and Wisniewski T (1996). The interaction between apolipoprotein E and Alzheimer's amyloid b-peptide is dependent on β-peptide conformation. J Biol Chem 271, 10602-10606
26. Biere AL, Ostaszewski B, Stimson ER, Hyman BT, Maggio JE and Selkoe DJ (1996). Amyloid β-peptide is transported on lipoproteins and albumin in human plasma. J Biol Chem 271, 32916-32922